BioPhoundry

Biophoundry is a biotechnology company that specializes in developing phage-based technologies to combat antibiotic resistance. The company has built a proprietary platform called Phax, which utilizes cell-free synthetic biology and machine learning to engineer and produce customized bacteriophages—viruses that target and kill specific bacteria—for use in therapeutics, diagnostics, and bio-molecular engineering. By moving from traditional, time-intensive phage discovery to a data-driven, scalable phage design process, the platform aims to provide personalized phage treatments that are significantly faster and more cost-effective to develop and manufacture than existing industry standards.

This technology is intended to support healthcare providers and researchers in addressing the growing global threat of antimicrobial resistance. By offering a rapid, on-demand solution for generating precision antibiotics, Biophoundry seeks to improve patient access to innovative, targeted therapies for recalcitrant infections. The company, headquartered in Chapel Hill, North Carolina, leverages a multidisciplinary team with expertise in systems engineering, synthetic biology, and artificial intelligence to validate their design tools and advance these solutions toward clinical applications.